Cipla ties up with US-based BioQ Pharma for supplying post-operative pain treatment drug

Drug major Cipla has inked a pact with US-based BioQ Pharma for registration and commercialisation of latter's Ropivacaine infusion system, used in treating post-operative pain, in India.


BioQ Pharma and Cipla have inked a strategic distribution, supply and development agreement for the registration and commercialisation of BioQ Pharma's Ropivacaine infusion pharmaceutical in India, the companies said in a joint statement.

"We believe this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain," Cipla's India Business Head, Nikhil Chopra said.

BioQ Pharma's unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.

In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution.

BioQ Pharma, President and CEO, Josh Kriesel said the company is excited to collaborate with Cipla and expand its worldwide commercial footprint into India.

"We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals," he added.

Cipla's proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to India's healthcare market, Kriesel said.


Updated Date: Jan 06, 2016 15:52 PM

Also Watch

Watch: Firstpost test rides the new Thunderbird 500X in Goa and walks you through the Royal Enfield Garage Cafe
  • Tuesday, April 17, 2018 Varun Dhawan on Shoojit Sircar's October, 5-star reviews and working with Anushka Sharma in Sui Dhaaga
  • Saturday, April 14, 2018 Ambedkar Jayanti: Re-visiting Babasaheb's ideals exposes fake Dalit politics of Rahul Gandhi and Congress
  • Monday, April 9, 2018 48 hours with Huawei P20 Pro: Triple camera offering is set to redefine smartphone imaging
  • Monday, April 16, 2018 Rajyavardhan Singh Rathore interview: Sports can't be anyone's fiefdom, we need an ecosystem to nurture raw talent

Also See

  • Arun Gupta exits pharma major Cipla

  • Cipla shares gains on partner's South Africa contract win

  • Cipla Q2 net up 62% on robust sales at Rs 500 cr